-
Puerto Vallarta: the Mexican paradise in flames over the killing of 'El Mencho'
-
Sorloth treble helps Atletico past Brugge into Champions League last 16
-
Louvre president hands in resignation to Macron: Elysee
-
Iran says deal 'within reach' ahead of US talks
-
Torrential rains leave 25 dead in Brazil, dozens missing
-
Northeast US faces power cuts and school closures after snowstorm
-
US abstains in UN vote voicing support for Ukraine
-
Lebanon fears Israeli strikes if Iran situation escalates
-
Trump seeks to strike back in crucial State of the Union
-
World-class Brook played 'the best innings of his life' - Afridi
-
US appeals WTO ruling in dispute by China over clean energy subsidies
-
Guadalajara: World Cup host city rocked by narco violence
-
Briiliant Brook 100 puts England into T20 World Cup semi-finals
-
Germany's Merz heads to China for talks centred on trade
-
Briiliant Brook 100 puts England into T20 World Cups semi-finals
-
Warner Bros. 'reviewing' new takeover bid from Paramount
-
US told EU it 'stands' by tariff deal: trade chief
-
Torrential rains leave 23 dead in Brazil, dozens missing
-
UK govt says will release files on 'rude' ex-prince Andrew
-
Nearly an own gull! CPR performed on bird at Turkey football match
-
How AFP has used data analysis to cover the Ukraine war
-
Paris says US envoy pledges not to 'interfere' in France affairs
-
Iran says students must respect 'red lines' after protests
-
Italian biathlete Giacomel has heart surgery after Olympic withdrawal
-
Gazans salvage ancient books in mosque library damaged by war
-
Farhan scores 63 as England restrict Pakistan to 164-9
-
Stocks bounce as traders assess AI fallout, tariffs
-
Brazil court tries politicians over hit on Black councilwoman
-
Senegal PM vows to double penalty for same-sex relations
-
UK govt backs releasing documents tied to 'rude' ex-prince Andrew
-
Novo Nordisk to slash prices of weightloss drugs in US
-
Welllage says Sri Lanka can rescue T20 World Cup campaign
-
UK's royal protection officers urged to speak up in Epstein probe
-
Aid groups petition Israel's top court to halt ban on Gaza, West Bank ops
-
UEFA can make fight against racism more than a slogan: Real Madrid's Arbeloa
-
Bali flooding prompts tourist evacuation: official
-
Jones says Borthwick's 'title-decider' comments behind England collapse
-
UK fines Reddit nearly $20 mn over children's data failures
-
PSG star Hakimi faces trial for alleged rape
-
Netflix, Prime and Disney+ face UK broadcasting regulation
-
Greece set new tourism record in 2025
-
Zelensky says Ukraine unbroken after 4 years, but Russia vows to fight on
-
Zelenksy says Ukraine unbroken after 4 years, but Russia vows to fight on
-
Snoop Dogg 'can't wait' for first Swansea visit
-
Stocks fluctuate as traders assess AI fallout, tariffs
-
Post-it maker 3M faces Belgian trial over 'forever' chemicals
-
UK comedian Russell Brand pleads not guilty to new rape, assault charges
-
Duterte drew up 'death lists', boasted about murders: ICC prosecutor
-
UK govt urged to release documents linked to ex-prince Andrew
-
Rights group slams treatment of viral Japanese monkey
Appetite-regulating hormones in focus as first Nobel Prizes fall
Research into hormones that regulate appetite is seen leading the race for the Nobel Prize in Medicine, to be awarded Monday -- the first in this year's Nobel season.
At a time when more than one billion people suffer from obesity, research into the hormone called "glucagon-like peptide 1" (GLP-1) could be given the nod for the Nobel Prize in Physiology or Medicine this year, experts said.
A new generation of drugs using GLP-1 agonists -- including blockbuster brands Ozempic, Wegovy and Mounjaro -- has provided a valuable tool to fight obesity and diabetes globally.
"Many are guessing that it (the Nobel Prize in Medicine) will go to the people behind GLP-1," Lars Brostrom, science editor at public broadcaster Sveriges Radio, told AFP.
That could help researchers from major US institutions once again dominate the Nobel Prizes in sciences, which are to be announced this week in Stockholm.
But, even if that happens, US politics is to cast a shadow over them, given budget cuts to science programmes ordered by President Donald Trump's government.
Since January, the US National Institutes of Health (NIH) has terminated 2,100 research grants totalling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch.
Such cuts could fuel debate over the growing risk that the United States could lose its edge in scientific research.
"In the post-war period, the US has taken over Germany's role as the world's leading scientific nation," Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel Prizes in physics, chemistry, and economics, told AFP.
"When they now start cutting research funding, it threatens the country's position."
- Many contenders -
When it comes to GLP-1, as with many other discoveries, it can be hard to narrow down who exactly deserves to be honoured when many scientists around the world have made significant contributions.
Brostrom said some names often speculated upon are Danish physician Jens Juul Holst, and Joel Habener, a professor of medicine at Harvard, as well as Canadian endocrinologist Daniel Drucker and Yugoslav-born American chemist Svetlana Mojsov.
Despite treatments such as Ozempic being recently introduced, and the Nobel Assembly at the Karolinska Institute more often honouring discoveries that are decades old, "it could also be perfect timing" for GLP-1 recognition "because the discovery itself was made back in the 80s", Brostrom said.
In the same field, research on ghrelin, a hormone that stimulates appetite, could earn a Nobel Prize for two Japanese researchers, Kenji Kangawa and Masayasu Kojima, according to David Pendlebury, who heads research analysis at the firm Clarivate -- which predicts potential Nobel winners based on the number of citations of their work.
Pendlebury said that would also form "a nice bookend to a 1994 discovery" by geneticist Jeffrey Friedman, who discovered another appetite-regulating hormone, leptin, and who has previously been spotlighted by Clarivate.
"We have a combination of very nice discoveries, a hormone for appetite, a hormone that suppresses appetite, and this may also play into a lot of speculation of a prize for the GLP-1," he told AFP.
Clarivate also said the work of German medical professor Andrea Ablasser, American virologist Glen N. Barber, and Chinese-American biochemist Zhijian "James" Chen could be honoured "for elucidating the cGAS-STING pathway, a fundamental mechanism of innate immunity".
It noted that Canadian biologist John E. Dick could also be a contender "for identifying leukaemia stem cells and establishing their relevance in therapy failure".
- 'Invisibility cloak' -
For the Nobel Prize in Physics on Tuesday, experts at Sweden's public radio cited research into metamaterials, which has been buzzed about for several years.
British physicist John B. Pendry has in particular been frequently mentioned for his "invisibility cloak" -- a theoretical method to redirect electromagnetic fields around an object.
The Nobel season continues Wednesday with the prize for chemistry, followed on Thursday by the closely watched literature prize and on Friday the peace prize, which Donald Trump has argued should go to him.
The economics prize wraps up the Nobel season on October 13.
In addition to each honour, the prize includes a diploma, a gold medal, and a check for 11 million Swedish kronor ($1.2 million).
J.Williams--AMWN